Insulin-like Growth Factor 1-Receptor Inhibitors in Thyroid
Thyroid eye disease (TED) is an autoimmune disorder that is believed to result from the stimulation of several receptors located in the orbital fibroblasts. It is frequently misdiagnosed, due to both the heterogeneity of clinical presentation and lack of understanding of the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at risk, as management is most effective during the initial active phase of the disease. However, differential diagnosis can be achieved with the assistance of imaging, and early treatment may limit disfigurement and reduce vision loss. Ophthalmologists, endocrinologists, and other clinicians who care for patients with TED should be knowledgeable about the conventional and new treatments available as well as how to apply this information to practice. In this CME activity, experts in the field will explore conventional and new treatment options, including teprotumumab, the first and only medical agent approved by the US Food and Drug Administration for the treatment of TED. The panel will explore the potential adverse effects associated with teprotumumab treatment, particularly hearing impairment, and will specifically address appropriate auditory testing and monitoring of patients being treated with teprotumumab.